Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook

Merck cuts $3 billion in costs as Keytruda reign nears end

Merck and Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world.

MSD plans $3bn cuts amid competition for Irish-manufactured cancer drug Keytruda

MSD employs more than 3,000 people at eight locations in Ireland

Merck Mounts $3 Billion Revamp as Keytruda Price Pressure Looms

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world.

2 injured, including 1 seriously, in Stamford crash involving a dump truck

Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline.  The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda in 2028, and braces for the Trump administration’s planned tariffs on pharmaceutical imported into the U.S. Merck also posted second-quarter revenue…

Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook

The multi-year effort comes as Merck prepares to offset revenue losses from the upcoming patent expiration of its blockbuster cancer drug Keytruda.